YONGIN, South Korea, Aug. 28, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Thailand Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial...
Hence then, the article about gc biopharma submits ind to begin phase 3 clinical trial for barycela in thailand was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand )
Also on site :
- This ‘Whimsical’ 100% Cotton Throw Blanket With Cottagecore Charm Is Giving Major Anthropologie Vibes for Under $20
- Rosen Law Firm Encourages Suja Life, Inc. Investors to Inquire About Securities Class Action Investigation - SUJA
- The IRS is scrutinizing how UnitedHealth moved money through foreign subsidiaries—and whether it underpaid taxes